Therefore, FGF23 should be further investigated as a promising target using FGF23-deficient mice or anti-FGF23 antibodies in Ctnnb1OE-SEC mice and in murine and human MDS. The gene discussed is FGF23; the disease is myelodysplastic syndrome.